Table 3.
Correlation of biomarkers with therapy response
| Responder | Non-Responder | |||||
|---|---|---|---|---|---|---|
| Marker | Time [hours] | Median | Range | Median | Range | p-Value |
|
Nucleosomes [ng/mL] |
0 | 198.5 | 17.4-1624 | 174.7 | 5.0-1617 | 0.991 |
| 24 | 239.1 | 55.6-1225 | 844.8 | 21.7-4334 | 0.003 | |
| 48 | 677.2 | 51.7-2095 | 594.9 | 133.3-2547 | 0.851 | |
|
CYFRA 21-1 [ng/mL] |
0 | 6.9 | 0.8-32.8 | 14.0 | 1.3-246.0 | 0.031 |
| 24 | 28.4 | 1.0-118.0 | 30.8 | 2.9-811.0 | 0.493 | |
| 48 | 19.6 | 1.5-404.0 | 28.5 | 2.6-638.0 | 0.293 | |
|
CEA [ng/mL] |
0 | 162.0 | 4.0-986.0 | 557.0 | 2.0-31620 | 0.037 |
| 24 | 265.5 | 2.6-5011 | 540.5 | 1.6-36120 | 0.087 | |
| 48 | 229.5 | 2.2-4073 | 524.0 | 1.6-37550 | 0.063 | |
|
CA 19-9 [U/L] |
0 | 18.6 | 2.4-159.0 | 148.0 | 2.4-11530 | 0.001 |
| 24 | 17.9 | 2.5-298.0 | 158.0 | 2.4-18550 | 0.004 | |
| 48 | 20.9 | 2.4-260.0 | 187.5 | 2.3-17000 | 0.002 | |
|
LDH [U/L] |
0 | 349.0 | 178.0-544.0 | 529.5 | 220.0-3068 | 0.011 |
| 24 | 450.0 | 143.0-1117 | 532.0 | 148.0-2923 | 0.522 | |
| 48 | 572.0 | 142.0-1488 | 607.5 | 168.0-3585 | 0.434 | |
|
CRP [mg/dL] |
0 | 0.9 | 0.3-5.1 | 2.4 | 0.1-20.3 | 0.227 |
| 24 | 1.1 | 0.1-2.8 | 2.8 | 0.2-21.8 | 0.159 | |
| 48 | 4.4 | 0.1-16.3 | 4.6 | 0.3-15.1 | 0.507 | |
|
AST [U/L] |
0 | 37.5 | 24.0-94.0 | 56.0 | 24.0-190.0 | 0.037 |
| 24 | 111.0 | 32.0-169.0 | 69.0 | 15.0-339.0 | 0.782 | |
| 48 | 85.0 | 33. 0-179.0 | 66.0 | 19.0-317.0 | 0.912 | |
|
ALT [U/L] |
0 | 38.0 | 15.0-63.0 | 30.0 | 15.0-268.0 | 0.658 |
| 24 | 52.0 | 26.0-131.0 | 37.0 | 14.0-178.0 | 0.108 | |
| 48 | 54.0 | 23.0-112.0 | 34.0 | 13.0-136.0 | 0.113 | |
|
GGT [U/L] |
0 | 183.5 | 44. 0-432.0 | 189.0 | 33.0-712.0 | 0.782 |
| 24 | 168.5 | 46.0-391.0 | 164.0 | 31.0-577.0 | 0.965 | |
| 48 | 177.5 | 60.0-406.0 | 170.0 | 31.0-653.0 | 0.903 | |
|
AP [U/L] |
0 | 153.0 | 89.0-569.0 | 193.0 | 81.0-742.0 | 0.559 |
| 24 | 156.0 | 78.0-588.0 | 151.0 | 63.0-655.0 | 0.707 | |
| 48 | 156.0 | 77.0-504.0 | 164.0 | 61. 0-630.0 | 0.674 | |
|
Bilirubin [mg/dL] |
0 | 0.7 | 0.3-1.4 | 0.8 | 0.3-1.9 | 0.438 |
| 24 | 0.9 | 0.4-1.7 | 1.0 | 0.4-2.2 | 0.920 | |
| 48 | 1.1 | 0.5-2.4 | 1.2 | 0.4-2.8 | 0.799 | |
|
CHE [kU/L] |
0 | 8.3 | 4.9-11.1 | 6.5 | 2.8-10.8 | 0.017 |
| 24 | 7.1 | 5.1-11.1 | 5.7 | 2.8-10.4 | 0.009 | |
| 48 | 6.9 | 4.5-10.5 | 5.3 | 2.3-9.7 | 0.006 | |
|
Amylase [U/L] |
0 | 64.5 | 20.0-105.0 | 54.0 | 24.0-136.0 | 0.346 |
| 24 | 45.5 | 21.0-79.0 | 44.0 | 20.0-429.0 | 0.833 | |
| 48 | 50.5 | 20.0-58.0 | 46.0 | 23.0-519.0 | 0.842 | |
|
Lipase [U/L] |
0 | 27.0 | 3.0-149.0 | 25.0 | 3.0-263.0 | 0.725 |
| 24 | 17.5 | 4.0-33.0 | 18.0 | 3.0-585.0 | 0.773 | |
| 48 | 16.5 | 3.0-42.0 | 22.0 | 3.0-495.0 | 0.330 | |
P-values (by Wilcoxon-test) are shown for the various response groups.
There was a significant correlation between therapy response and survival time in this setting (s = 0.034). (Figure 2A).